Philogen (PHIL) Q3 2025 earnings summary

Executive summary

• Net financial position as of 30 September 2025 is positive at €369.2 million, reflecting a significant increase in liquidity and financial strength.

• Major clinical progress reported for Nidlegy™ and Fibromun, with expanded studies and new trials initiated in skin cancers and soft tissue sarcoma.

• Stock grant plans for 2024-2026 and 2027-2029 cycles implemented, with partial achievement of performance objectives and new grants allocated.

Financial highlights

• Liquidity increased from €100.0 million on 30 June 2025 to €380.3 million on 30 September 2025, up 280%.

• Net financial position improved by 317% quarter-over-quarter, mainly due to €299.2 million in customer contract inflows.

• Current and non-current financial indebtedness decreased by 2.7% sequentially, primarily from lease amortization.

Outlook and guidance

• Strong liquidity enables the launch of new clinical studies and further pipeline expansion.

• Plans to initiate a confirmatory Phase III trial for Fibromun in STS with OS as the primary endpoint in 2026.

• Preparations underway for a registrational Phase III study of 68Ga-OncoCAIX.